AMGN heads into the back half of August riding an 18% one-month surge, yet the positioning data tells a more cautious story beneath the surface.
The most striking feature of the current setup is the distance the stock has travelled in a short time. AMGN gained roughly 18% over the past month and added another 0.6% on the week, even after a 1.1% slip on Friday. The most recent earnings print, released August 4, crystallised the rally: the stock jumped 7% the next day and held most of that gain through the following week, finishing the five-day window up 9.4%. With the next results not due until November 5, the immediate catalyst picture is quieter — but the post-earnings momentum has left the stock trading above where analysts appear comfortable.
Short positioning is worth watching even though it is not extreme. The utilization rank comes in at the 70th percentile — meaning Amgen's borrow market is tighter than roughly 70% of its universe — while the short score rank at the 60th percentile suggests a modest but not aggressive bear lean. Cost-to-borrow data is too dated to be reliable here, so the clearest readable signal on borrow friction is that utilization percentile, which points to a lending pool that is meaningfully used but not at a stress point. There is no sign of a squeeze setup, but there is also no sign that shorts are abandoning the thesis.
The Street picture is one of muted conviction. The analyst recommendation differential scores in only the 2nd percentile — essentially the weakest possible consensus — implying the aggregate rating barely tilts positive. Against that, EPS momentum has been building, with a 63rd-percentile reading over 30 days and a 59th-percentile reading over 90 days. The EPS surprise score at 33 is below average, which fits the recent note flagging that Q2 was soft relative to consensus. The valuation picture is worth noting cautiously: a prior stock-score analysis put the price-to-book near 20.7x and flagged a negative target-price differential, meaning the stock was already trading above the average analyst price target even before the latest leg higher. No fresh analyst targets are available to reconcile with the current price, so readers should treat any older Street numbers with care given how far the stock has moved.
Institutional ownership is broad and broadly stable. BlackRock holds roughly 9.1% of shares, with Vanguard, Capital Research, and State Street each holding between 5% and 7%. Most of the largest holders added modestly in the most recent reported period — nothing dramatic, but consistent with index-driven inflows rather than a conviction call. The dividend score ranks in the 99th percentile, a reminder that Amgen's yield remains one of the more compelling in large-cap biotech, even if the dividend history in the snapshot is stale and should not be relied on for current figures.
The setup heading into the rest of August is defined by the tension between a stock that has already repriced sharply higher and a positioning backdrop that has not fully capitulated. The key variable to track is whether the post-earnings momentum continues to attract fresh institutional buying, or whether the above-consensus-target price level draws renewed short interest ahead of November results.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
